iCAD to Participate in the Cowen 41st Annual Health Care Conference
NASHUA, N.H.,
March 03, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will
deliver a formal presentation at the Cowen 41st Annual Health Care
Conference on Thursday, March 4th at 12:10pm ET and will also
conduct one-on-one meetings with investors.
A live audio
webcast of the presentation will be available by clicking https://wsw.com/webcast/cowen81/icad/1908885, as well as on
the “Events & Webcasts” section of iCAD’s investor website, https://www.icadmed.com/financial-news-and-events.html. A
replay of the webcast will be available on the Company’s website.
About
iCAD, Inc.
Headquartered
in Nashua, NH, iCAD is a global medical technology leader providing innovative
cancer detection and therapy solutions.
ProFound AI™
is a high-performing workflow solution for 2D and 3D mammography, or digital
breast tomosynthesis (DBT), featuring the latest in deep-learning artificial
intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT)
became the first artificial intelligence (AI) software for DBT to be
FDA-cleared; it was also CE marked and Health Canada licensed that same year.
It offers clinically proven time-savings benefits to radiologists, including a
reduction of reading time by 52.7 percent, thereby halving the amount of time
it takes radiologists to read 3D mammography datasets. Additionally, ProFound
AI for DBT improved radiologist sensitivity by 8 percent and reduced
unnecessary patient recall rates by 7.2 percent.
The Xoft
System is FDA-cleared, CE marked and licensed in a growing number of countries
for the treatment of cancer anywhere in the body. It uses a proprietary
miniaturized x-ray source to deliver a precise, concentrated dose of radiation
directly to the tumor site, while minimizing risk of damage to healthy tissue
in nearby areas of the body.
For more
information, visit www.icadmed.com and www.xoftinc.com.
Forward-Looking
Statements
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements about the future prospects for the Company’s
technology platforms and products. Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited, to the Company’s ability to achieve business and strategic
objectives, the ability of IORT to alleviate the burden to our health system
and minimize a patient’s potential exposure to Covid-19, to be more beneficial
for patients that traditional therapy or to be accepted by patients or
clinicians, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, to defend itself in litigation matters,
protection of patents and other proprietary rights, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible
technological obsolescence of products, increased competition, litigation
and/or government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website
at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568